- THC Global’s new name to reflect strategic developments, established global operations and international partnerships
- Recognises significant value THC Global is creating now and into the future, across both medicinal and recreational cannabis markets
- New name captures growth objectives and direction for the Company as a leading medicinal cannabis business with global significant operations
- Tier one growing and manufacturing capacity in Australia and ability to supply and expand internationally
- THC Global’s supply capacity is now among the world’s largest cannabis producers
THC Global Group Limited is pleased to advise that the Company’s name has changed from The Hydroponics Company (ASX:THC).
The ASX code “THC” remains unchanged. The change of the Company name was approved by shareholders at the Extraordinary General Meeting held on 15 November.
Shareholders supported the directors when considering the new name, which better reflects the strategic developments in the business, the importance of advancing established global operations and international partnerships and recognises the significant value THC Global is now creating and into the future, across both medicinal and recreational cannabis markets.
THC Global believes the new name also captures the growth objectives and direction for the Company as a leading medicinal cannabis business with tier one growing and manufacturing capacity in Australia and ability to supply and expand internationally.
Chief Executive Officer, Ken Charteris, commented:
“THC Global is preparing to enter new international markets and secure a stronghold as a full-scale global cannabis producer. The name change reflects our established operations, partnerships and alliances and our global expansion plans. We are particularly excited by the potential to increase our revenue generation in Canada in the coming months.”
THC Global will continue to expand its Vancouver-based revenue generating hydroponics division (Crystal Mountain), which sells equipment and growing mediums, while accelerating the build out of its medicinal cannabis growing and manufacturing facilities under its ‘Farm to Pharma’ pharmaceutical model.